Tolerizing Immune Modifying Nanoparticles for Overcoming the Immunogenicity of Therapeutic Vectors and Proteins
AssigneeCour Pharmaceuticals Development Company, Inc.
InventorsJohn Puisis, Adam Elhofy, Joseph Podojil, Michael Boyne, Tushar Murthy
Life of this patent
Estimating the term…
Abstract
The present application is directed, in general, to tolerizing immune mediated particles comprising gene therapy vector antigens for use in combination with gene therapy regimens in order to reduce immunogenicity to the gene therapy vector antigens and/or transgene protein products expressed by the vectors.
Claims65
A composition comprising negatively charged particles encapsulating an antigen, wherein the antigen is one or more gene therapy vector antigens, portions thereof, or combinations thereof and/or one or more transgene protein products produced by a gene therapy vector(s), portions thereof, or combinations thereof.
The composition of 8, wherein the viral vector is an adenovirus, adeno-associated virus (AAV), herpes simplex virus, hepatitis B virus, lentivirus, retrovirus, alphavirus, flavivirus, rhabdovirus, measles virus, Newcastle disease virus, coxsackieviruses, transfusion transmitted viruses, anellosomes, human papilloma viruses, poxvirus, vaccinia virus, modified Ankara virus, vesicular stomatitis virus, picornavirus, tobacco mosaic virus, cowpea mosaic virus, cowpea chlorotic mottle virus, physalis mosaic virus, red clover necrotic mosaic virus, potato virus x, comovirus, chicken anemia virus or cucumber mosaic virus.
A method of inducing tolerance to a subject in need thereof comprising administering to a subject a composition comprising negatively charged particles encapsulating an antigen, wherein the antigen is one or more gene therapy vector antigens and/or one or more transgene protein products produced by the gene therapy vector(s), portions, or combinations thereof.
A composition comprising liposomes encapsulating one or more gene therapy vector antigens, portions, or combinations thereof.
A composition comprising liposomes encapsulating therapeutic proteins produced by the gene therapy vector and/or a portion thereof.
Dependencies are inferred from the claim text.